C. Escuriola‐Ettingshausen

965 citations

22 papers · 466 indexed · h-index 11

Co-authors: W. Kreuz B. Kornhuber H. Schmidt U. Martinowitz M. Heim Michele Jönsson Funk C. A. Lee Johannes Oldenburg
Topics: Hemophilia Treatment and Research (22 papers)Platelet Disorders and Treatments (11 papers)Blood Coagulation and Thrombosis Mechanisms (6 papers)
Cited by: Hematology Genetics Oncology
Journals: Blood Thrombosis and Haemostasis Journal of Thrombosis and Haemostasis
Partner nations: Germany United States France

In The Last Decade

C. Escuriola‐Ettingshausen

20 papers receiving 444 citations

Peers

Countries citing papers authored by C. Escuriola‐Ettingshausen

Since Specialization

Citations

This map shows the geographic impact of C. Escuriola‐Ettingshausen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Escuriola‐Ettingshausen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Escuriola‐Ettingshausen more than expected).

Fields of papers citing papers by C. Escuriola‐Ettingshausen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Escuriola‐Ettingshausen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Escuriola‐Ettingshausen. The network helps show where C. Escuriola‐Ettingshausen may publish in the future.

Co-authorship network of co-authors of C. Escuriola‐Ettingshausen

This figure shows the co-authorship network connecting the top 25 collaborators of C. Escuriola‐Ettingshausen. A scholar is included among the top collaborators of C. Escuriola‐Ettingshausen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Escuriola‐Ettingshausen. C. Escuriola‐Ettingshausen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PB0680 Clinical Characteristics, Therapy and Outcome of Children with Hemophilia B and Inhibitors: a PedNet Study 2023 ·Research and Practice in Thrombosis and Haemostasis ·(unknown),(unknown),Helen Pergantou,Roseline d’Oiron,Beatrice Nolan,C. Escuriola‐Ettingshausen,Kathelijn Fischer,Nadine G. Andersson,Heidi Glosli,María Román,Jayashree Motwani,Gili Kenet,Christoph Male	0
2	Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, phase 3 PROPEL study 2023 ·Therapeutic Advances in Hematology ·C. Escuriola‐Ettingshausen,Robert Klamroth,Miguel A. Escobar,Oleksandra Stasyshyn,Srilatha Tangada,Werner Engl,(unknown),Hye-Youn Lee,Pratima Chowdary,Jerzy Windyga	0
3	Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021 2021 ·Research and Practice in Thrombosis and Haemostasis ·Yesim Dargaud,C. Escuriola‐Ettingshausen	8
4	Pharmacokinetic-Guided Prophylaxis with Rurioctocog Alfa Pegol Improves Bleeding Rates over Standard Prophylaxis: Real-World Observational Data from the Ahead German Study 2021 ·Blood ·Robert Klamroth,Karin Kurnik,(unknown),C. Escuriola‐Ettingshausen,(unknown),(unknown),Joan Gu,(unknown),Johannes Oldenburg	1
5	Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel 2020 ·Haemophilia ·C. Escuriola‐Ettingshausen,Günter Auerswald,Christoph Königs,Karin Kurnik,Ute Scholz,Robert Klamroth,Johannes Oldenburg	28
6	Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A 2020 ·Hämostaseologie ·Katharina Holstein,Manuela Albisetti,Christoph Bidlingmaier,Susan Halimeh,Sabine Heine,Robert Klamroth,Christoph Königs,Karin Kurnik,Christoph Male,Johannes Oldenburg,Werner Streif,C. Wermes,C. Escuriola‐Ettingshausen,(unknown)	23
7	The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab 2019 ·Haemophilia ·Manuel Carção,C. Escuriola‐Ettingshausen,Elena Santagostino,Johannes Oldenburg,Ri Liesner,Beatrice Nolan,Angelika Bátorová,Saturnino Haya,Guy Young,(unknown)	72
8	Immune tolerance induction: What have we learned over time? 2018 ·Haemophilia ·H.‐H. Brackmann,G C White,Erik Berntorp,Tina Veje Andersen,C. Escuriola‐Ettingshausen	39
9	Prophylaxis re‐visited: The potential impact of novel factor and non‐factor therapies on prophylaxis 2018 ·Haemophilia ·Manuel Carção,Thierry Lambert,Cindy Leissinger,C. Escuriola‐Ettingshausen,Elena Santagostino,Louis M. Aledort,(unknown)	6
10	Intensity of factor VIII treatment and the development of inhibitors in non‐severe hemophilia A patients: results of the INSIGHT case–control study 2017 ·Journal of Thrombosis and Haemostasis ·Alice S. van Velzen,Corien L. Eckhardt,Marjolein Peters,Frank W.G. Leebeek,C. Escuriola‐Ettingshausen,Cédric Hermans,Russell Keenan,Jan Astermark,Christoph Male,Kathelijne Peerlinck,Saskia le Cessie,Johanna G. van der Bom,Karin Fijnvandraat	28
11	Challenges of the management of severe hemophilia A with inhibitors 2015 ·Blood Coagulation & Fibrinolysis ·Sophie Mathieu,(unknown),Yesim Dargaud,Géraldine Lavigne-Lissalde,C. Escuriola‐Ettingshausen,Brigitte Tardy,(unknown),Sandrine Thouvenin,Jean Louis Stéphan,Claire Berger	4
12	Hemophilia Prophylaxis No Longer Just for Children without Inhibitors - Increasing Use of Prophylaxis in Other Groups (children with inhibitors and adults with and without inhibitors) 2015 ·Blood ·Manuel Carção,Laura Avila,Victor S. Blanchette,Elena Santagostino,C. Escuriola‐Ettingshausen,Cindy Leissinger,Thierry Lambert,Louis M. Aledort	2
13	Inhibitors in haemophilia A - Prevention, current management and personalised therapy perspectives 2011 ·Thrombosis and Haemostasis ·Erik Berntorp,C. Escuriola‐Ettingshausen,Kate Khair,W. Kreuz,(unknown),(unknown)	1
14	ITI with a VWF-Stabilised FVIII Concentrate in Haemophilia A Patients with Inhibitors and a Poor Prognosis for ITI Success: Progress Report on octanate® in the Observational ObsITI Study, 2011 ·Blood ·C. Escuriola‐Ettingshausen,(unknown),(unknown),(unknown),W. Kreuz,Bruce A. Schwartz	3
15	The application of bypassing‐agent prophylaxis in haemophilia A patients with inhibitors: a meeting report 2009 ·Haemophilia ·Leonard A. Valentino,Manuel Carção,Prasad Mathew,Cindy Leissinger,Erik Berntorp,Victor S. Blanchette,C. Escuriola‐Ettingshausen,Bruce M. Ewenstein,Nadia P. Ewing,A. Gringeri,W. Keith Hoots,Claude Négrier	11
16	Epidemiology of Inhibitor Development in Haemophilia A Patients Treated with Virus‐Inactivated Plasma‐Derived Clotting Factor Concentrates 1999 ·Vox Sanguinis ·W. Kreuz,C. Escuriola‐Ettingshausen,Inmaculada Martinez‐Saguer,(unknown),B. Kornhuber	1
17	Epidemiology of Inhibitor Development in Haemophilia A Patients Treated with Virus– Inactivated Plasma–Derived Clotting Factor Concentrates 1999 ·Vox Sanguinis ·W. Kreuz,C. Escuriola‐Ettingshausen,Inmaculada Martinez‐Saguer,(unknown),B. Kornhuber	12
18	When should prophylactic treatment in patients with haemophilia A and B start?— The German experience 1998 ·Haemophilia ·C. A. Lee,(unknown),(unknown),U. Martinowitz,M. Heim,W. Kreuz,C. Escuriola‐Ettingshausen,Michele Jönsson Funk,H. Schmidt,B. Kornhuber	131
19	Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis 1998 ·Annals of Hematology ·Markus B. Funk,H. Schmidt,C. Escuriola‐Ettingshausen,S. Pons,(unknown),(unknown),B. Kornhuber,W. Kreuz	38
20	Epidemiology of Inhibitors inHaemophilia A 1996 ·Vox Sanguinis ·(unknown),C. Escuriola‐Ettingshausen,(unknown),(unknown),(unknown)	2

About C. Escuriola‐Ettingshausen

C. Escuriola‐Ettingshausen is a scholar working on Hematology, Genetics and Molecular Biology, having authored 22 papers that have together received 466 indexed citations. Recurring topics across this work include Hemophilia Treatment and Research (22 papers), Platelet Disorders and Treatments (11 papers) and Blood Coagulation and Thrombosis Mechanisms (6 papers). The work is most often cited by research in Hematology (455 citations), Genetics (129 citations) and Oncology (24 citations). C. Escuriola‐Ettingshausen has collaborated with scholars based in Germany, United States and France. Frequent co-authors include W. Kreuz, B. Kornhuber, H. Schmidt, U. Martinowitz, M. Heim, Michele Jönsson Funk, C. A. Lee, Johannes Oldenburg, Manuel Carção and G C White. Their work appears in journals such as Blood, Thrombosis and Haemostasis and Journal of Thrombosis and Haemostasis.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact